The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion

Genes, Chromosomes & Cancer
Ruth N MacKinnonLynda J Campbell

Abstract

Deletion of the long arm of one chromosome 20 (del(20q)) is a well-recognized abnormality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is presumed to cause loss of a tumor suppressor gene at 20q12. In a previously published series of MDS and AML cases, which had lost this region via unbalanced translocation, around 40% of cases were shown to have additional copies of the chromosome 20 abnormalities, with resulting gain or amplification of the retained parts of chromosome 20, most often 20q11.2. We have used FISH and array comparative genomic hybridization, to define further the retained and amplified regions. We now report targeted amplification of 20q11.21 in four of the 22 cases selected for further study and in one new case. The shortest amplified region of 250 kb in a series of five patients with three to ten copies of the 20q11.21 region contained the complete HCK, TM9SF4, PLAGL2, and POFUT1 genes. By RT-PCR we have shown that there is correlation between amplification and increased expression of these four genes in most cases. Localized and high level amplification of the common 250 kb region is evidence for activation of an oncogene in this region in these MDS and AML cases. Cases with 20q11.21...Continue Reading

References

Sep 15, 1992·Cancer·S Heim, F Mitelman
Feb 1, 1992·Cancer Genetics and Cytogenetics·K OhyashikiK Toyama
Jun 1, 1989·Molecular and Cellular Biology·S F ZieglerR M Perlmutter
Jun 1, 1987·Molecular and Cellular Biology·S F ZieglerR M Perlmutter
Mar 1, 1987·British Journal of Haematology·E J LeeJ R Testa
May 1, 1984·Cancer Genetics and Cytogenetics·M P DavisH C Hoagland
Feb 1, 1996·Cancer Genetics and Cytogenetics·I KubonishiI Miyoshi
Jul 1, 1996·Leukemia Research·J Anastasi
Nov 1, 1996·American Journal of Clinical Pathology·P J KurtinC A Hanson
May 5, 1998·Molecular and Cellular Biology·J F BrombergJ E Darnell
Jun 13, 2000·The Journal of Biological Chemistry·J M LionbergerT E Smithgall
Nov 28, 2001·European Journal of Haematology·K SpiekermannF Alves
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Sep 24, 2002·The Journal of Biological Chemistry·Steven J SchreinerThomas E Smithgall
Nov 2, 2002·The EMBO Journal·Agata KlejmanTomasz Skorski
May 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Juan LiAnthony R Green
Aug 31, 2004·Genes, Chromosomes & Cancer·Donal MacGroganStephen D Nimer
Jun 21, 2005·Experimental Hematology·Malcolm A S Moore
Jul 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank G RückerHartmut Döhner
Oct 24, 2006·Leukemia Research·Lu FuShuji Tohda
Nov 30, 2006·Methods in Enzymology·Linchao Lu, Pamela Stanley
Feb 27, 2007·Cancer Genetics and Cytogenetics·Stephanie A SmoleyGordon W Dewald
Dec 7, 2007·Blood·Cédric Dos SantosChristian Récher
Jan 19, 2008·Nature·Kevin M Shannon, Michelle M Le Beau
Feb 7, 2008·Cytogenetic and Genome Research·R N Mackinnon, L J Campbell
Mar 19, 2008·The Journal of Biological Chemistry·Mark StahlPamela Stanley
Sep 18, 2008·Journal of Cell Science·Evelyne BergeretMarie-Odile Fauvarque
Nov 28, 2008·British Journal of Haematology·N Douet-GuilbertM De Braekeleer

❮ Previous
Next ❯

Citations

Nov 15, 2011·Apoptosis : an International Journal on Programmed Cell Death·Tracey S Hanks, Katherine A Gauss
Jan 19, 2012·Nature Reviews. Molecular Cell Biology·Marieke A M FrasaVania M M Braga
Jan 1, 2011·Genetics Research International·Ruth N Mackinnon, Lynda J Campbell
Oct 18, 2011·Trends in Molecular Medicine·Stefano Fais, Marie-Odile Fauvarque
Feb 1, 2014·Evolution, Medicine, and Public Health·Ruth N MackinnonLynda J Campbell
Sep 6, 2017·Scientific Reports·Qibin SongShiang Huang
Sep 26, 2013·International Journal of Oncology·Satoshi YokotaKatsuhiro Uzawa
Oct 7, 2015·International Journal of Hematology·Chunxiao WuYanlei Gong
Jun 4, 2020·Cancers·Marlène DeschuyterAbderrahman Maftah
Nov 2, 2018·Cancers·Julien ChabanaisAbderrahman Maftah
Nov 14, 2018·Nature Reviews. Cancer·Stefano Fais, Michael Overholtzer
Jun 5, 2021·Medical Hypotheses·Antonio Mazzocca, Stefano Fais
Dec 21, 2020·Molecular Aspects of Medicine·Kenjiroo MatsumotoRobert S Haltiwanger
Jul 24, 2021·British Journal of Haematology·Iván MartínUNKNOWN Spanish Group of Myelodysplastic Syndromes (GESMD)
Jul 13, 2021·Journal of Bioenergetics and Biomembranes·Qi LiLei Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.